After suffering through doldrums recently, some biotech public offerings this year have been successful and might inspire other IPOs, writes Luke Timmerman. Investments are up as more general-interest investors return to the sector, larger companies are acquiring smaller firms and Congress seems likely to broaden the scope of accelerated approvals. "The real question is, at what point do bigger funds, not just health care specialists, move in to biotech?" asks Bob Nelsen, a managing director at Arch Venture Partners.
Published in Brief: